Anavex

$6.16
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.36 (+6.26%) Today

+$0.05 (+0.82%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Anavex and other stocks, options, and ETFs commission-free!

About AVXL

Anavex Life Sciences Corp. Common Stock, also called Anavex, is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY. The listed name for AVXL is Anavex Life Sciences Corp. Common Stock.

CEO

Christopher U. Missling

Employees

Headquarters

New York, New York

Founded

2004

Market Cap

414.12M

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

714.68K

High Today

$6.14

Low Today

$5.67

Open Price

$5.67

Volume

1.08M

52 Week High

$7.69

52 Week Low

$2.20

Collections

AVXL Earnings

-$0.17

-$0.11

-$0.06

$0.00

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Q1 FY21

Estimated

— per share

Actual

Expected Feb 4, Pre-Market